Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Phase 1 Active not recruiting 21 enrolled Tessa Therapeutics

NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma

Timeline

Start: 2021-09-08
Primary completion: 2022-11-22
Completion: 2036-03

Publications

Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD30.CAR-T	Cell therapy	2e+08 cells	—
Subject	CD30.CAR-T	Cell therapy	4e+08 cells	—
Subject	CD30.CAR-T	Cell therapy	6e+08 cells	—
Background	Bendamustine	Small molecule	—	—
Background	Fludarabine	Small molecule	—	—

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Summary

Timeline

Publications

Drugs

Indications